Principal Health Economist
Phil joined BresMed in 2017 after previously working for the University of York where he critiqued manufacturer submissions for health technology appraisals (HTAs) for the National Institute of Health and Care Excellence (NICE) as a member of their Technology Assessment Group. At York, Phil also obtained both an MSc in Health Economics and a BSc in Economics.
Phil has worked on the construction and adaptation of numerous economic models and has extensive experience in both developing and critiquing UK HTAs, having worked on over 10 submissions to both NICE and the Scottish Medicines Consortium. He has experience across a range of disease areas, most notably in prostate cancer, non-Hodgkin’s lymphoma, multiple myeloma, psoriasis and a number of orphan indications.